SynCore Biotechnology Co Ltd (4192) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SynCore Biotechnology Co Ltd (4192) has a cash flow conversion efficiency ratio of -0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-7.18 Million ≈ $-226.11K USD) by net assets (NT$257.97 Million ≈ $8.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SynCore Biotechnology Co Ltd market capitalisation for the company's overall valuation and market capitalisation.
SynCore Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how SynCore Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SynCore Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SynCore Biotechnology Co Ltd ranked by their cash flow conversion efficiency. Explore 4192 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Photon Energy N.V.
WAR:PEN
|
0.119x |
|
Fabrity Holding S.A.
WAR:FAB
|
0.028x |
|
Linkhome Holdings Inc. Common stock
NASDAQ:LHAI
|
-0.431x |
|
Rapid Synergy Bhd
KLSE:7765
|
-0.138x |
|
SyntekaBio Inc
KQ:226330
|
-0.098x |
|
Law Debenture Corp
LSE:LWDB
|
0.023x |
|
YX Precious Metals Bhd
KLSE:0250
|
-0.028x |
|
CodeMill AB
ST:CDMIL
|
0.052x |
Annual Cash Flow Conversion Efficiency for SynCore Biotechnology Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of SynCore Biotechnology Co Ltd from 2015 to 2024. View latest SynCore Biotechnology Co Ltd stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$294.69 Million ≈ $9.28 Million |
NT$-49.24 Million ≈ $-1.55 Million |
-0.167x | +27.55% |
| 2023-12-31 | NT$357.14 Million ≈ $11.25 Million |
NT$-82.37 Million ≈ $-2.60 Million |
-0.231x | +72.60% |
| 2022-12-31 | NT$249.01 Million ≈ $7.85 Million |
NT$-209.61 Million ≈ $-6.60 Million |
-0.842x | -62.20% |
| 2021-12-31 | NT$442.92 Million ≈ $13.95 Million |
NT$-229.86 Million ≈ $-7.24 Million |
-0.519x | +8.12% |
| 2020-12-31 | NT$560.58 Million ≈ $17.66 Million |
NT$-316.63 Million ≈ $-9.98 Million |
-0.565x | +17.41% |
| 2019-12-31 | NT$612.03 Million ≈ $19.28 Million |
NT$-418.57 Million ≈ $-13.19 Million |
-0.684x | -77.52% |
| 2018-12-31 | NT$706.70 Million ≈ $22.26 Million |
NT$-272.26 Million ≈ $-8.58 Million |
-0.385x | -37.46% |
| 2017-12-31 | NT$720.61 Million ≈ $22.70 Million |
NT$-201.96 Million ≈ $-6.36 Million |
-0.280x | -38.83% |
| 2016-12-31 | NT$966.36 Million ≈ $30.45 Million |
NT$-195.09 Million ≈ $-6.15 Million |
-0.202x | -9.04% |
| 2015-12-31 | NT$842.81 Million ≈ $26.55 Million |
NT$-156.03 Million ≈ $-4.92 Million |
-0.185x | -- |
About SynCore Biotechnology Co Ltd
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the trea… Read more